

Overview

Propanc Biopharma is a clinical stage biopharmaceutical company developing new cancer treatments for solid tumors. Propanc has developed a formulation of anti-cancer compounds designed to control or prevent tumors from recurring and spreading throughout the body by using proenzymes, which are inactive precursors of enzymes.

Propanc intends to target patients with limited therapeutic options for treatment of solid tumors, initially pancreatic, ovarian or colorectal tumors. Propanc achieved Orphan Drug Designation from the FDA for the treatment of pancreatic cancer. Propanc is also developing its lead product, PRP, to treat early stage cancer and pre-cancerous diseases and as a preventative measure for patients at risk of developing cancer, based on genetic screening.

Stock Data

Price (04-28-21)	\$0.19
Market Cap	\$1.0 M
Avg. Daily Volume (30D)	75,584
Outstanding Shares	5,298,862
52 week High and Low	\$16.00/ \$0.18

Investment Highlights

Targeted Therapy for Metastatic Cancer:

No effective standard treatments exist for solid tumors. Tumor cells return to the normal pathways of a differentiated cell.

Multiple Mechanisms of Action


PRP is a novel technology with a large scale global potential that not only treats metastatic cancer but reduces the rate of recurrence.

Unique Intellectual Property

The Company is building a robust patent portfolio around its scientific understanding of the effects of pro-enzymes in cancer, new formulations, new routes of administration, and potential new targets.

PRP is designed to eradicate Cancer Stem Cells

- Mixture of two proenzymes, trypsinogen & chymotrypsinogen from the bovine pancreas.
- PRP induces cell differentiation, converting cancerous cells into normal cells.
- Compassionate use patient data shows statistically significant results.
- PRP is a patented approach that:
 - Suppresses tumor metastasis and relapse.
 - Complements conventional anti-cancer therapies.
 - Is safe at specified dosages with minimal toxicity.
 - Is not cytotoxic (toxic to living cells)
- A synergistic ratio of 1:6 inhibits growth of most tumor cells.
- Examples include ovarian and colorectal cancers.
- Has also shown efficacy in kidney, breast, brain, prostate, lung, liver, uterine, and skin cancers.



Expansive Market Demand:

Approximately 80% of cancers are from solid tumors, and metastasis is the main cause of patient death. Proenzyme therapy targets and eradicates cancer stem cells not killed by radiation or chemotherapy.

Encouraging Patient Data

15 years of scientific research and clinical experience suggest PRP has the potential to convert cancerous cells back into normal cells.

International Strategic Partnerships

The Company maintains research partnerships with the University of Bath, University of Jaén, University of Grenada and the Foundation for Biosanitary Research of Andalusia Orients.

Compassionate Use Data

- 46 terminal patients (UK & AUS) administered two proenzymes plus amylase via suppository.
- Independent review concluded 19 patients significantly exceeded life expectancy.
- Response rate comparable to cytotoxic or immunologic approaches at Phase 1.
- No severe or even serious adverse effects.
- Most showed improved quality of life and relief of symptoms.
- Increased dose may result in better therapeutic efficacy.

Propanc Innovation & Intellectual Property

- Sixty five patents in force and pending covering several important discoveries regarding proenzymes and their anti-cancer effects:
 - Pharmaceutical composition for treating cancer
 - Proenzyme compositions
 - Cancer treatment (eradicating CSCs)
 - Composition of proenzymes for cancer treatment
- Lead patent approved in several countries including the US & EU.

PRP Development Timeline

	2021				2022			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
GMP Manufacture / Bioanalytics								
Obtain Regulatory Approval for Phase IB								
Phase IB, F.I.H. study								

Mr James Nathanielsz Chief Executive Officer

- Director and Chief Executive Officer since October 2007
- 20 years of experience in R&D, manufacturing, and distribution including 10 years in oncology and the development of chemotherapeutics
- Bachelor of Applied Science, (Biochemistry/ Applied Chemistry) and Master of Entrepreneurship & Innovation, Swinburne University of Technology, Melbourne, Australia

Dr Julian Kenyon Chief Scientific Officer

- Founded the company and appointed Director on February 12, 2008
- Medical Director of the Dove Clinic for Integrated Medicine, UK since 2000
- Bachelor of Medicine and Surgery and Doctor of Medicine, University of Liverpool
- Primary Fellow of the Royal College of Surgeons, Edinburgh for over 40 years

Prof Klaus Kutz Chief Medical Officer

- 20 years of experience as independent consultant in clinical pharmacology and safety in oncology for pharmaceutical companies and clinical research organizations
- 12 years of experience as Head of Pharmacology in 2 multinational pharmaceutical companies
- Specialist for Internal Medicine, Gastroenterology, and Clinical Pharmacology
- Professor of Medicine, University of Bonn, Germany

Legal Contact

John O’Leary
Patrizio & O’Leary
609-786-2525
jlucosky@lucbro.com

Media Contact

Josef Zelinger
Propanc Biopharma, Inc.
Investor Relations
irteam@propanc.com

Company Contact

James Nathanielsz
Chief Executive Officer
302/6 Butler Street, Camberwell
Victoria, 3124, Australia

CONFIDENTIAL INFORMATION. This information is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy any security or related financial instrument. The summary may include “forward-looking statements” with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934 and are intended to be covered by the safe harbor provisions for forward looking statements. This information is supplied from sources we believe to be reliable but we cannot guarantee accuracy. This document and the information contained herein is confidential. This document has been furnished to you solely for your information. The information contained herein may not be reproduced, disclosed or redistributed, in whole or in part, by mail, facsimile, electronic or computer transmission or by any other means to any other person, except with prior written consent of the Company. The material has been prepared or is distributed solely for information purposes and is not a solicitation or an offer to buy any security or instrument or to participate in any trading strategy.